What is the 13F Pro Quality Score for INSM?

13F Pro ranks INSMED Inc (INSM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INSM's current score at https://13fpro.ai/company/INSM (free sign-up required for the full ranking).

Which hedge funds own the most INSM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INSM include FMR, BlackRock,, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/INSM as soon as new 13F filings post.

Where does 13F Pro source INSM data?

All INSMED Inc fundamentals and ownership data come directly from SEC EDGAR. INSMED Inc files with the SEC under CIK 1104506. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INSM in?

INSMED Inc (INSM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INSM research updated on 13F Pro?

INSM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INSMED Inc(INSM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1104506 INSM stock profile & AI dashboard →

13F Pro Quality Score

39.4/100

Rank #2,150 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

96.4/100

Profitability

8.8/100

Balance Sheet

5.6/100

Earnings Quality

14.5/100

Free Cash Flow

7.6/100

Institutional Flow

83.2/100

Revenue Scale

52.2/100

Dilution Risk

7.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why INSM Scores 39/100

exact factor attribution · 2026-09-11

INSM's composite is driven by revenue growth and institutional flow, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.3 pts

96th pct

Institutional flow

+1.7 pts

83th pct

Earnings growth

+0.8 pts

66th pct

Scale

+0.3 pts

52th pct

Shareholder dilution

-2.1 pts

7th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-4.4 pts

6th pct

Profitability

-6.2 pts

9th pct

Free cash flow

-6.4 pts

8th pct

Latest change (2026-08-06): 29 → 27 · ↓ Revenue growth 92→82

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

INSM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for INSMED Inc (INSM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INSM at 39.4/100 on a 32-signal composite quality model, placing it at rank #2,150 of 2,961 stocks — the bottom half of the AI-ranked universe. INSM scores in the top quartile across revenue growth (96.4), institutional flow (83.2). Areas of concern include balance sheet strength (5.6) and free cash flow (7.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), INSMED Inc reports quarterly revenue of $425.5M, net income of $-13.2M, free cash flow of $-95.1M. Top institutional holders of INSM by reported 13-F value include FMR, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. INSM trades on the Nasdaq exchange and files with the SEC under CIK 1104506. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INSMED Inc directly from SEC EDGAR. INSMED Inc's 13F Pro composite quality score has ranged between 18 and 39 since 2021, currently 39.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about INSMED Inc

Quirks, history, and lore behind INSM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the low hundreds of millions and climbing fast — but like most clinical-stage-turned-commercial biotechs, it has spent years running at a net loss while building its pipeline.
3
The History
Founded in 2000, it spent its early years as a quiet rare-disease researcher before landing a breakthrough therapy designation from the FDA and pivoting to commercial-stage operations.
4
The Secret
Its entire commercial bet is riding on one rare lung disease — a condition so uncommon that most doctors will never see a single patient with it in their career.
5
The Lore
The disease it targets, bronchiectasis caused by a rare infection, has been neglected for decades — making this company essentially the only game in town for patients who had no approved treatment.
6
The Giveaway
Its flagship drug Arikayce — an inhaled amikacin therapy — treats Mycobacterium avium complex (MAC) lung disease, a battle this Bridgewater biotech has been fighting almost alone.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$425.5M

Net Income

Q2 2026

$-13.2M

Free Cash Flow

Q2 2026

$-95.1M

ROIC

Q2 2026

-0.5%

D/E Ratio

Q2 2026

0.72

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+66.7% YoY

$606.4MFY 2025

FY22 $245.4MFY23 $305.2MFY24 $363.7MFY25 $606.4M

Net Income

-39.7% YoY

$-1.28BFY 2025

FY22 $-481.5MFY23 $-749.6MFY24 $-913.8MFY25 $-1.28B

Operating Income

-42.0% YoY

$-1.25BFY 2025

FY22 $-457.3MFY23 $-709.6MFY24 $-878.3MFY25 $-1.25B

EPS (Diluted)

-15.3% YoY

$-6.42FY 2025

FY22 $-3.91FY23 $-5.34FY24 $-5.57FY25 $-6.42

Total Assets

+11.8% YoY

$2.26BFY 2025

FY22 $1.66BFY23 $1.33BFY24 $2.03BFY25 $2.26B

Total Debt

-51.3% YoY

$546.8MFY 2025

FY22 $1.15BFY23 $1.18BFY24 $1.12BFY25 $546.8M

Op. Cash Flow

-36.7% YoY

$-935.0MFY 2025

FY22 $-400.4MFY23 $-536.2MFY24 $-683.9MFY25 $-935.0M

Free Cash Flow

-37.1% YoY

$-967.6MFY 2025

FY22 $-410.3MFY23 $-549.5MFY24 $-705.8MFY25 $-967.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$606.4M +66.7%	$363.7M +19.2%	$305.2M +24.4%	$245.4M +30.2%	$188.5M +14.6%	$164.4M
Net Income	$-1.28B -39.7%	$-913.8M -21.9%	$-749.6M -55.7%	$-481.5M -10.8%	$-434.7M -47.8%	$-294.1M
Operating Income	$-1.25B -42.0%	$-878.3M -23.8%	$-709.6M -55.2%	$-457.3M -21.9%	$-375.1M -41.4%	$-265.2M
EPS (Diluted)	$-6.42 -15.3%	$-5.57 -4.3%	$-5.34 -36.6%	$-3.91 -0.8%	$-3.88 -28.9%	$-3.01
Total Assets	$2.26B +11.8%	$2.03B +52.3%	$1.33B -19.7%	$1.66B +33.2%	$1.24B +56.2%	$796.2M
Total Debt	$546.8M -51.3%	$1.12B -4.7%	$1.18B +2.0%	$1.15B +44.3%	$800.0M +77.8%	$450.0M
Operating Cash Flow	$-935.0M -36.7%	$-683.9M -27.5%	$-536.2M -33.9%	$-400.4M -10.2%	$-363.3M -65.6%	$-219.3M
Free Cash Flow	$-967.6M -37.1%	$-705.8M -28.4%	$-549.5M -33.9%	$-410.3M -10.7%	$-370.6M -64.3%	$-225.6M

Get alerted when INSM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INSMED Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INSM

FMR LLC
$1.7B16,143,583 sh
BlackRock, Inc.
$1.7B15,807,984 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.1B10,407,962 sh
JPMORGAN CHASE & CO
$1.1B10,428,170 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0B9,790,865 sh
BAKER BROS. ADVISORS LP
$937.8M8,796,111 sh
Capital International Investors
$878.3M8,238,124 sh
Darwin Global Management, Ltd.
$673.6M6,431,163 sh
AMERIPRISE FINANCIAL INC
$658.9M6,179,571 sh
Orbis Allan Gray Ltd
$647.9M6,076,487 sh

Fund	Value	Shares
FMR LLC	$1.7B	16,143,583
BlackRock, Inc.	$1.7B	15,807,984
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.1B	10,407,962
JPMORGAN CHASE & CO	$1.1B	10,428,170
VANGUARD CAPITAL MANAGEMENT LLC	$1.0B	9,790,865
BAKER BROS. ADVISORS LP	$937.8M	8,796,111
Capital International Investors	$878.3M	8,238,124
Darwin Global Management, Ltd.	$673.6M	6,431,163
AMERIPRISE FINANCIAL INC	$658.9M	6,179,571
Orbis Allan Gray Ltd	$647.9M	6,076,487

Companies Similar to INSM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 29 shared holders

BAKER BROS. ADVISORS LP RTW INVESTMENTS, LP Artisan Partners Limited Partnership

AXSM

Axsome Therapeutics, Inc.

AI score

Very similar · 24 shared holders

Hood River Capital Management LLC Integral Health Asset Management, LLC FRONTIER CAPITAL MANAGEMENT CO LLC

NTRA

Natera, Inc.

AI score

Very similar · 33 shared holders

Duquesne Family Office LLC RTW INVESTMENTS, LP MAVERICK CAPITAL LTD

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

AI score

Very similar · 20 shared holders

BAKER BROS. ADVISORS LP Hood River Capital Management LLC EVENTIDE ASSET MANAGEMENT, LLC

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 26 shared holders

Hood River Capital Management LLC Polar Capital Holdings Plc Bellevue Group AG

RARE

Ultragenyx Pharmaceutical Inc.

AI score

Very similar · 21 shared holders

RTW INVESTMENTS, LP FRONTIER CAPITAL MANAGEMENT CO LLC Bellevue Group AG

GKOS

GLAUKOS Corp

AI score

Very similar · 23 shared holders

JENNISON ASSOCIATES LLC WESTFIELD CAPITAL MANAGEMENT CO LP WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 22 shared holders

Polar Capital Holdings Plc Clearbridge Investments, LLC WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INSM on your watchlist

Track score changes the day INSMED Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INSM a good stock to buy?

13F Pro's AI-powered analysis of INSMED Inc (INSM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INSM are available on the INSM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INSM is classified as a large company.

Which hedge funds own INSM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INSM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INSMED Inc's investment landscape.